Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Mark Rubinstein and Carsten Krieg.
Mark Rubinstein
Connection Strength
0.455
Carsten Krieg
  1. Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers. J Immunol. 2022 03 15; 208(6):1362-1370.
    View in: PubMed
    Score: 0.207
  2. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
    View in: PubMed
    Score: 0.158
  3. IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors. Cancer Res. 2020 09 15; 80(18):3920-3932.
    View in: PubMed
    Score: 0.046
  4. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-?. Sci Transl Med. 2020 01 08; 12(525).
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.